AdAPT

American Society of Clinical Oncology (ASCO) Annual Meeting 2023

June 2023; Chicago, Illinois
Poster: RRX-001 Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001 TGF-ß Trap (NCT04673942)

Poster: RRX-001, KEVLARx: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. SOC in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).

SITC 2023 Spring Scientific

March 2023, Denver Colorado
Poster: TRIAL-IN-PROGRESS BETA-PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors (NCT04673942)
Poster: Low dose but not high dose RRx-001 repolarizes tumor associated macrophages from an M2 to M1 phenotype in colorectal cancer

3rd TGF-B for Immuno-Oncology Drug Development Summit 2023

January 2023, San Francisco, California
Oral Presentation: Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001

  • Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001
  • Using correlative studies for measuring expression in the clinic
  • Discussing neutralizing TGF-β for improving checkpoint inhibitors

San Antonio Breast Cancer Summit (SABCS) 2022

December 2022, San Antonio, Texas
Poster: Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial